David Gaiero Net Worth

The estimated Net Worth of David G Gaiero is at least $42.3 Thousand dollars as of 3 February 2020. Mr. Gaiero owns over 651 units of Wave Life Sciences stock worth over $37,713 and over the last 5 years he sold WVE stock worth over $4,557. In addition, he makes $0 as Interim Chief Financial Officer at Wave Life Sciences.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Gaiero WVE stock SEC Form 4 insiders trading

David has made over 1 trades of the Wave Life Sciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 651 units of WVE stock worth $4,557 on 3 February 2020.

The largest trade he's ever made was selling 651 units of Wave Life Sciences stock on 3 February 2020 worth over $4,557. On average, David trades about 326 units every 0 days since 2020. As of 3 February 2020 he still owns at least 6,392 units of Wave Life Sciences stock.

You can see the complete history of Mr. Gaiero stock trades at the bottom of the page.

David Gaiero biography

David G. Gaiero serves as Interim Chief Financial Officer of the Company. Prior to this appointment, Mr. Gaiero served as our Vice President, Corporate Controller since July 2017. Prior to joining us, from 2015 to 2017 Mr. Gaiero served as Vice President, Global Controller of OvaScience, Inc. and from 2007 to 2015 he held various positions of increasing responsibility and scope in finance and accounting at iRobot Corporation. Mr. Gaiero began his career in public accounting at PricewaterhouseCoopers, LLP. Mr. Gaiero received a Bachelor of Business Administration in Accounting from the University of Massachusetts, Amherst, and is a Certified Public Accountant in Massachusetts.

How old is David Gaiero?

David Gaiero is 41, he's been the Interim Chief Financial Officer of Wave Life Sciences since 2020. There are 18 older and no younger executives at Wave Life Sciences. The oldest executive at Wave Life Sciences Ltd. is Koji Miura, 71, who is the Independent Director.

What's David Gaiero's mailing address?

David's mailing address filed with the SEC is C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE, MA, 02138.

Insiders trading at Wave Life Sciences

Over the last 9 years, insiders at Wave Life Sciences have traded over $19,158,839 worth of Wave Life Sciences stock and bought 18,619,108 units worth $128,204,225 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Ra ..., and Capital Management, Llc Kol.... On average, Wave Life Sciences executives and independent directors trade stock every 43 days with the average trade being worth of $1,569,819. The most recent stock trade was executed by Paul Bolno on 21 August 2024, trading 48,366 units of WVE stock currently worth $279,555.

What does Wave Life Sciences do?

wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.

Complete history of Mr. Gaiero stock trades at Wave Life Sciences

Wave Life Sciences executives and stock owners

Wave Life Sciences executives and other stock owners filed with the SEC include:

• Paul Bolno,
  President, Chief Executive Officer, Director
• Christopher Francis,
  Senior Vice President - Corporate Development, Head of Emerging Areas
• Michael Panzara,
  Chief Medical Officer
• Chandra Vargeese,
  Senior Vice President, Head of Drug Discovery
• Dr. Paul B. Bolno M.B.A., M.D., MBA,
  Pres, CEO & Director
• Dr. Michael A. Panzara M.D., M.P.H., MPH,
  Chief Medical Officer and Head of Therapeutics Discovery & Devel.
• Dr. Chandra Vargeese Ph.D.,
  Chief Technology Officer
• Gregory Verdine,
  Director
• Mark Corrigan,
  Independent Director
• Amy Pott,
  Independent Director
• Heidi Wagner,
  Independent Director
• Christian Henry,
  Independent Chairman of the Board
• Peter Kolchinsky,
  Independent Director
• Ken Takanashi,
  Independent Director
• Adrian Rawcliffe,
  Independent Director
• Koji Miura,
  Independent Director
• Kenneth Rhodes,
  Senior Vice President - Therapeutics Discovery
• David Gaiero,
  Interim Chief Financial Officer
• Kate Rausch,
  Investor Relations
• Anne-Marie Li-Kwai-Cheung,
  Sr. VP of Regulatory Affairs, Compliance & Policy
• Dr. Sridhar Vaddeboina Ph.D.,
  Sr. VP of Chemistry, Manufacturing & Controls
• Jose Juves,
  Sr. VP of Corp. Affairs & Patient Advocacy
• Jonathan Rosin,
  Chief HR Officer
• Dr. Christopher Francis Ph.D.,
  Sr. VP of Corp. Devel. & Head of Emerging Areas
• Linda Rockett J.D.,
  Gen. Counsel
• Kyle B. Moran CFA,
  CFO & Principal Accounting Officer
• Chris Francis,
  See Remarks
• Plc Gsk,
  10% owner
• Keith Regnante,
  Chief Financial Officer
• Takeshi Wada,
  Director
• Ken Shin Nippon Biomedical ...,
  
• Masaharu Kagoshima Shinsang...,
  
• Roberto Guerciolini,
  See Remarks
• Masaharu Tanaka,
  Director
• Peter Kolchinsky,
  Director
• Capital Management, Llc Kol...,
  
• Mark Baldry,
  Chief Commerical Officer
• Capital Management, L.P.Ra ...,
  
• Kyle Moran,
  Chief Financial Officer
• Aik Na Tan,